Investors are taking a closer look at healthcare stocks in 2026 as money moves away from high-priced technology companies. Three names are drawing the most attention: Eli Lilly, Abbott Laboratories, and Johnson & Johnson.
Eli Lilly has become one of the biggest growth stories in healthcare.
The company leads the obesity and diabetes drug market through its GLP-1 treatments Mounjaro and Zepbound. Demand for these drugs continues to grow globally, and analysts expect them to stay major revenue drivers for years.
JPMorgan recently reaffirmed its positive outlook on the stock, pointing to growing Medicare adoption and continued momentum from obesity treatments.
Beyond weight loss, Lilly has a deep drug pipeline covering oncology, neuroscience, immunology, and metabolic disease. The company has invested heavily in manufacturing capacity and acquisitions to support that growth.
Lilly trades at a premium, but analysts say the valuation reflects one of the strongest earnings growth profiles in the pharmaceutical industry.
Abbott Laboratories takes a different approach from a pure-play drug company.
The company runs a diversified business across medical devices, diagnostics, nutrition, and established pharmaceuticals. That mix has helped it produce steady earnings through different economic conditions.
Abbott’s FreeStyle Libre glucose monitoring platform is a standout in diabetes care. Its cardiovascular devices and diagnostics units are also growing as global populations age and demand for healthcare rises.
The company generates reliable cash flow, which it uses to invest in new products and pay a steadily growing dividend.
Johnson & Johnson has sharpened its focus after separating its consumer health business.
The company now concentrates on pharmaceuticals and medical technology. Its oncology portfolio is growing, led by strong demand for Darzalex. The drug recently received European approval, and the company continues to expand its cancer treatment pipeline ahead of upcoming earnings.
Cardiovascular and surgical devices are also delivering healthy growth. Johnson & Johnson has raised its dividend for more than six decades, making it a reliable income stock for long-term holders.
Healthcare is drawing investor interest for clear reasons. Ageing populations, rising demand for advanced treatments, and strong pharmaceutical pipelines are all driving the sector forward in 2026.
Eli Lilly offers the strongest growth potential. Abbott brings diversification and stability. Johnson & Johnson combines innovative medicines with one of the longest dividend growth records on the market.
Together, the three stocks give investors broad exposure to pharmaceuticals, medical devices, diagnostics, and defensive healthcare spending.
The post Best Healthcare Stocks for Long-Term Investors in 2026 appeared first on CoinCentral.
